Locally advanced cervical cancer: Is it relevant to report image-guided adaptive brachytherapy using point A dose?

In patients treated with IGABT, point A dose is not predictive of local control but a surrogate of the irradiated volume. Its relationships with the D90 CTVHR are indirect and complex rising the question of relevance of its reporting in routine.